Ipca Laboratories Past Earnings Performance
Past criteria checks 2/6
Ipca Laboratories's earnings have been declining at an average annual rate of -3.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 10.7% per year. Ipca Laboratories's return on equity is 7.9%, and it has net margins of 7.9%.
Key information
-3.5%
Earnings growth rate
-3.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 10.7% |
| Return on equity | 7.9% |
| Net Margin | 7.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Aug 09Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Jun 08How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?
Mar 26Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?
Mar 13Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently
Feb 28Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 23Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?
Feb 11Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?
Jan 30The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It
Jan 15Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Dec 31
Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Dec 16The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?
Dec 13This Insider Has Just Sold Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Nov 28Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Nov 25Ipca Laboratories Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 10Is Ipca Laboratories Limited's (NSE:IPCALAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Nov 08Do Insiders Own Lots Of Shares In Ipca Laboratories Limited (NSE:IPCALAB)?
Oct 24Ipca Laboratories' (NSE:IPCALAB) Wonderful 327% Share Price Increase Shows How Capitalism Can Build Wealth
Oct 09What We Learned About Ipca Laboratories' (NSE:IPCALAB) CEO Compensation
Sep 24Revenue & Expenses BreakdownBeta
How Ipca Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 71,875 | 5,643 | 15,923 | 0 |
| 30 Sep 23 | 66,806 | 4,922 | 14,517 | 0 |
| 30 Jun 23 | 62,500 | 4,911 | 13,450 | 0 |
| 31 Mar 23 | 62,481 | 4,713 | 13,102 | 0 |
| 31 Dec 22 | 60,225 | 5,250 | 12,779 | 0 |
| 30 Sep 22 | 59,070 | 6,142 | 12,431 | 0 |
| 30 Jun 22 | 58,505 | 7,205 | 12,204 | 0 |
| 31 Mar 22 | 58,305 | 8,841 | 11,972 | 0 |
| 31 Dec 21 | 56,561 | 9,152 | 11,555 | 0 |
| 30 Sep 21 | 56,355 | 9,837 | 11,169 | 0 |
| 30 Jun 21 | 54,521 | 10,005 | 10,751 | 0 |
| 31 Mar 21 | 54,207 | 11,400 | 10,318 | 0 |
| 31 Dec 20 | 53,802 | 10,647 | 10,135 | 0 |
| 30 Sep 20 | 51,833 | 9,968 | 9,997 | 0 |
| 30 Jun 20 | 51,061 | 9,228 | 9,772 | 0 |
| 31 Mar 20 | 46,499 | 6,063 | 9,366 | 0 |
| 31 Dec 19 | 44,563 | 6,189 | 8,911 | 0 |
| 30 Sep 19 | 42,496 | 5,804 | 8,455 | 0 |
| 30 Jun 19 | 39,777 | 5,059 | 8,254 | 0 |
| 31 Mar 19 | 37,750 | 4,448 | 8,123 | 0 |
| 31 Mar 18 | 32,852 | 2,394 | 7,604 | 0 |
| 31 Mar 17 | 31,562 | 1,945 | 7,182 | 0 |
| 31 Mar 16 | 28,671 | 931 | 6,474 | 0 |
| 31 Mar 15 | 31,444 | 2,542 | 5,872 | 0 |
| 31 Mar 14 | 32,818 | 4,785 | 9,200 | 852 |
Quality Earnings: IPCALAB has high quality earnings.
Growing Profit Margin: IPCALAB's current net profit margins (7.9%) are lower than last year (8.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IPCALAB's earnings have declined by 3.5% per year over the past 5 years.
Accelerating Growth: IPCALAB's earnings growth over the past year (7.5%) exceeds its 5-year average (-3.5% per year).
Earnings vs Industry: IPCALAB earnings growth over the past year (7.5%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: IPCALAB's Return on Equity (7.9%) is considered low.